% | $
Quotes you view appear here for quick access.

AstraZeneca PLC Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • dmagman dmagman Apr 27, 2012 10:08 AM Flag

    Well, this certainly means the dividend will be cut at least in half.

    One big question/issue is what the company will do to replace sales that are lost to generics and refill the pipeline. I doubt that we will see a drastic change in strategy in the near-term. Once a new full-time CEO is in place, and the new chairman is fully integrated, they will need to document that strategy. I doubt that it will be the same as it is now (I would guess that major shareholders would not be happy if it were). How much of a change, and its implications, will be proposed by the new folks at the top. Where the dividend goes long-term depends on what the new strategy is and how they will implement it. Same goes for the share buybacks that AZN has done over the past few years.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • would expect that the Co's strategy team has already lined up a plan to refresh their pipeline

      wouldn't you?

      There's too much at stake if things look so obvious with regards to their Portfolio Patent erosion.. calls for a NEXIUM like year huh?

      • 1 Reply to binndazz
      • Their current plan is to use single-digit billion dollar deals (like the recent purchase of Ardea for a billion and a quarter) to refill the pipeline. Another bigger deal, the size of MedImmune, would not have been considered.

        My point was that it seems unlikely that the new chairman/CEO combination will stick to the same plan. I'm not sure how they will change it, but I would expect to see a new/different strategy once they are in place.

29.28+0.320(+1.10%)May 2 4:02 PMEDT